All News

psA.fil_.Hands_.jpg

Novel and Emerging Therapies in Psoriatic Arthritis

Antoni Chan, MD, PhD

Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.

Read Article
artificial intelligence machine learning computer

ICYMI: Taking AI Out of AutoImmunity: Predicting disease before it develops

Akhil Sood, MD

the predictive value of a positive ANA test—especially in the absence of other clinical symptoms—remains a challenge. A positive test often leads to further testing, yet it does not necessarily indicate whether a patient truly has an underlying autoimmune disease. The development of AI and machine learning algorithms presents an opportunity to interpret autoantibody tests and predict autoimmune diseases. Here are three studies looking at this issue.

Read Article
search bar

ICYMI: How Online Searches Reveal Patient Needs

Bella Mehta, MBBS, MS

Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and treatment-related searches for rheumatic conditions.

Read Article
artificial intelligence machine learning computer

Predicting flares in rheumatic diseases with machine learning

Antoni Chan, MD, PhD

Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.

Read Article
Where there’s smoke, there’s flare: how pollution fuels RA The WHO has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 #ACR24 https://t.co/efVzSHXN91 https://t.co/AxRyGpqQFa

Links:

Dr. John Cush RheumNow ( View Tweet)
🌟IgG4RD: Lessons from the first 20 years🌟by Prof John Stone ⭐️Lesson 1- IgG4RD is a variable vessel vasculitis ✨Can cause small vessel vasculitis of the skin ✨One of few vasculitis causing coronary arteritis in adults ⭐️Lesson 2- IgG4RD is more common and severe in males… https://t.co/PvFXyOl5bp https://t.co/hAMelBoZvB

Links:

Darpan Thakare darpan06T ( View Tweet)
Day 1 Recap at #ACR24 Panelists Dr. Sheila Reyes, Dr. Adela Castro, Dr. Mike Putman and Dr. Jack Cush recap the most interesting abstracts and presentations they saw on day 1 of ACR 2024. https://t.co/8M0WhOLETg https://t.co/hW5cgRiy6F

Links:

Dr. John Cush RheumNow ( View Tweet)
Cognitive Impairment: The Hidden Burden in Lupus Care Suppose you have a patient with SLE returning for follow-up. Their joint symptoms are well controlled. The kidneys—managed with a combination of biologic DMARD and mycophenolate—show no signs of active urinary sediment or… https://t.co/W8RO5aOaxj https://t.co/EF9P93hdPB
Dr. John Cush RheumNow ( View Tweet)
Aging Gracefully in Managing Rheumatic Diseases Dr. Mrinalini Dey and Dr. Elena Myasoedova review highlights from a session on aging presented at #ACR24. https://t.co/tyT5d0JsEG https://t.co/szfDsSuWBx

Links:

Dr. John Cush RheumNow ( View Tweet)
Up-front Secukinumab in PsA? We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the… https://t.co/OAQOutluPe https://t.co/gLfG840DBP
Dr. John Cush RheumNow ( View Tweet)
Health Literacy: the forgotten social determinant of health? Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to… https://t.co/686bWffD2z https://t.co/TFyzgJ3NeL
Dr. John Cush RheumNow ( View Tweet)
ORAL Surveillance - Is Statin Use the Problem/Solution? The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate. https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd

Links:

Dr. John Cush RheumNow ( View Tweet)
Health Literacy: the forgotten social determinant of health? Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to… https://t.co/15gvQxZHNN https://t.co/VqCjZY4tYI
Dr. John Cush RheumNow ( View Tweet)
Abstract 2681: #SDOH factors & SLE risk: - Low income (AOR=2.779). - By race/ethnicity NHB (AOR=2.429), Hispanic (AOR=1.616). Behavioral: Psych distress (AOR=2.127), no exercise (AOR=1.677). Access: Medicaid (AOR=2.540), transport barriers (AOR=20.394). @RheumNow #ACR24

Akhil Sood MD AkhilSoodMD ( View Tweet)

For daily recaps, content and updates from #ACR24 head to https://t.co/eL0bMhnFiu @RheumNow with input from colleagues in the faculty @synovialjoints @bella_mehta @ericdeinmd @AkhilSoodMD. @DrMiniDey @CaoilfhionnMD @ebrhuem @rheumarampa @Dr_Brian_MD @AdelaCastro222 @JihaRheum… https://t.co/a3FQjGokhn https://t.co/1g3Fi01HWG

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

Hypoxia seems to exacerbate neutrophil activation by ANCA - enhanced F-Actin polymerization - enhanced NET formation Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns? @RheumNow #ACR24 https://t.co/KxaeMvkd2t

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
In Vivo CAR T Cell Therapy. A single intralymphatic injection of VivoVec™ particles: - Generates functional CAR T cells in vivo - Achieves complete B cell depletion in NHPs without lymphodepletion - Demonstrates potential for an off-the-shelf solution for autoimmune disease… https://t.co/5DTzRvZjbY https://t.co/DvTOqnhn1V

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Wt ⬇️ = Better #PROs in 👇autoimmune #rheumatic #diseases if > 5% wt loss. #ACR24 ⁦@ACRheum⁩ ⁦@RheumNow⁩ Didn’t work for non overwt Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx

Links:

Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×